Literature DB >> 31282009

Ochronotic pigmentation is caused by homogentisic acid and is the key event in alkaptonuria leading to the destructive consequences of the disease-A review.

Lakshminarayan R Ranganath1,2, Brendan P Norman2, James A Gallagher2.   

Abstract

Ochronosis is the process in alkaptonuria (AKU) that causes all the debilitating morbidity. The process involves selective deposition of homogentisic acid (HGA)-derived pigment in tissues altering the properties of these tissues, leading to their failure. Some tissues like cartilage are more easily affected by ochronosis while others such as the liver and brain are unaffected for reasons that are still not understood. In vitro and mouse models of ochronosis have confirmed the dose relationships between HGA and ochronosis and also their modulation by p-hydroxyphenylpyruvate dioxygenase inhibition. Ochronosis cannot be fully reversed and is a key factor in influencing treatment decisions. Earlier detection of ochronosis preferably by noninvasive means is desirable. A cause-effect relationship between HGA and ochronosis is discussed. The similarity in AKU and familial hypercholesterolaemia is explored and lessons learnt. More research is needed to more fully understand the crucial nature of ochronosis.
© 2019 SSIEM.

Entities:  

Keywords:  alkaptonuria; homogentisic acid; in vitro; natural history; ochronosis; pigment; severity

Year:  2019        PMID: 31282009     DOI: 10.1002/jimd.12152

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  8 in total

1.  Reversal of ochronotic pigmentation in alkaptonuria following nitisinone therapy: Analysis of data from the United Kingdom National Alkaptonuria Centre.

Authors:  Lakshminarayan R Ranganath; Anna M Milan; Andrew T Hughes; Milad Khedr; Andrew S Davison; Peter J Wilson; Jane P Dillon; Elizabeth West; James A Gallagher
Journal:  JIMD Rep       Date:  2020-06-22

2.  Metabolomic studies in the inborn error of metabolism alkaptonuria reveal new biotransformations in tyrosine metabolism.

Authors:  Brendan P Norman; Andrew S Davison; Juliette H Hughes; Hazel Sutherland; Peter Jm Wilson; Neil G Berry; Andrew T Hughes; Anna M Milan; Jonathan C Jarvis; Norman B Roberts; Lakshminarayan R Ranganath; George Bou-Gharios; James A Gallagher
Journal:  Genes Dis       Date:  2021-02-22

Review 3.  Alkaptonuria: Current Perspectives.

Authors:  Andrea Zatkova; Lakshminarayan Ranganath; Ludevit Kadasi
Journal:  Appl Clin Genet       Date:  2020-01-23

4.  Treatment of osteoporotic fractures in alkaptonuria by teriparatide stimulates bone formation and decreases fracture rate - A report of two cases.

Authors:  L R Ranganath; M Khedr; A Mistry; S Vinjamuri; J A Gallagher
Journal:  Bone Rep       Date:  2021-11-28

5.  Comparing nitisinone 2 mg and 10 mg in the treatment of alkaptonuria-An approach using statistical modelling.

Authors:  Lakshminarayan R Ranganath; Anna M Milan; Andrew T Hughes; Milad Khedr; Brendan P Norman; Mohammed Alsbou; Richard Imrich; Matthew Gornall; Nicolas Sireau; James A Gallagher; Richard Jackson
Journal:  JIMD Rep       Date:  2021-11-11

6.  Pigmentation Chemistry and Radical-Based Collagen Degradation in Alkaptonuria and Osteoarthritic Cartilage.

Authors:  Wing Ying Chow; Brendan P Norman; Norman B Roberts; Lakshminarayan R Ranganath; Christian Teutloff; Robert Bittl; Melinda J Duer; James A Gallagher; Hartmut Oschkinat
Journal:  Angew Chem Int Ed Engl       Date:  2020-05-14       Impact factor: 15.336

7.  A patient survey on the impact of alkaptonuria symptoms as perceived by the patients and their experiences of receiving diagnosis and care.

Authors:  Mattias Rudebeck; Ciarán Scott; Nicolas Sireau; Lakshminarayan Ranganath
Journal:  JIMD Rep       Date:  2020-03-07

8.  Expression of tyrosine pathway enzymes in mice demonstrates that homogentisate 1,2-dioxygenase deficiency in the liver is responsible for homogentisic acid-derived ochronotic pigmentation.

Authors:  Peter J M Wilson; Lakshminarayan R Ranganath; George Bou-Gharios; James A Gallagher; Juliette H Hughes
Journal:  JIMD Rep       Date:  2020-11-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.